Patents by Inventor Mark Uden

Mark Uden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11098312
    Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: August 24, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Robyn Alexandra Emmins, Gary Brian Finka, Michael Hoare, Alan Peter Lewis, William John Kenneth Lewis, Adam Daniel McInally, Mark Uden, Ioannis Voulgaris
  • Publication number: 20200339663
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Application
    Filed: May 12, 2020
    Publication date: October 29, 2020
    Inventors: Valeriu DAMIAN, Austin Keith Doyle, Laura Maria Halo, Emma R. Harding, Xuan Hong, Alan Peter Lewis, Mark Uden
  • Patent number: 10633673
    Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: April 28, 2020
    Assignee: GLAXO GROUP LIMITED
    Inventors: Mark Uden, Ekaterini Kotsopoulou
  • Publication number: 20190225708
    Abstract: The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also relates to compositions comprising said variant IgG4 antibodies.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 25, 2019
    Inventors: Hella BOSTEELS, Shugui CHEN, Kayeleigh FARROW, Richard KUCIA-TRAN, William John Kenneth LEWIS, Andrew S. THOMSON, Mark UDEN
  • Publication number: 20190177734
    Abstract: The present invention relates to a recombinant signal sequence derived from E. coli. The invention also relates to a fusion protein comprising the signal sequence, a recombinant protein and methods of producing the recombinant protein. The recombinant signal sequence can be used to provide a method for controlling the viscosity of the fermentation, and/or controlling basal (pre-induction) expression of the recombinant protein.
    Type: Application
    Filed: May 4, 2017
    Publication date: June 13, 2019
    Inventors: Robyn Alexandra EMMINS, Gary Brian FINKA, Michael HOARE, Alan Peter LEWIS, William John Kenneth LEWIS, Adam Daniel McINALLY, Mark UDEN, Ioannis VOULGARIS
  • Publication number: 20180222964
    Abstract: The present invention relates to methods of selecting, screening, engineering, making and modifying antibodies that have improved bioavailability upon subcutaneous administration to a human. Antibodies and variant antibodies with improved bioavailability upon subcutaneous administration to a human are also described.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 9, 2018
    Inventors: Valeriu DAMIAN, Austin Keith DOYLE, Laura Maria HALO, Emma R. HARDING, Xuan HONG, Alan Peter LEWIS, Mark UDEN
  • Publication number: 20180135008
    Abstract: The present invention relates to a method of producing a recombinant protein in a host cell comprising adding Polyethyleneimine (PEI) during cell culture. Addition of PEI to the cell culture as a fermentation enhancer can result in reducing the viscosity of the cell culture, and/or increasing the extracellular concentration of the recombinant protein, and/or reducing the duration of cell culture to the point of harvest or protein recovery.
    Type: Application
    Filed: May 13, 2016
    Publication date: May 17, 2018
    Inventors: Gary Brian FINKA, Michael HOARE, Mark UDEN, Ioannis VOULGARIS
  • Patent number: 9534246
    Abstract: The invention provides methods for the rapid identification and selection of cell lines suitable for biopharmaceuticals production, which do no utilize animal derived components.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: January 3, 2017
    Assignee: Glaxo Group Limited
    Inventors: Ekaterini Kotsopoulou, Richard Priest, Mark Uden
  • Publication number: 20160010111
    Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.
    Type: Application
    Filed: September 30, 2015
    Publication date: January 14, 2016
    Inventors: Mark UDEN, Ekaterini Kotsopoulou
  • Patent number: 9163249
    Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: October 20, 2015
    Assignee: Glaxo Group Limited
    Inventors: Mark Uden, Ekaterini Kotsopoulou
  • Publication number: 20130310281
    Abstract: The present invention provides novel antigen-binding proteins derived from human germline VH domains, having improved expression and improved biophysical characteristics.
    Type: Application
    Filed: January 27, 2012
    Publication date: November 21, 2013
    Applicant: Glaxo Group Limited
    Inventors: Emma R. Harding, Ekaterini Kotsopoulou, Alan Peter Lewis, Susannah Thornhill, Mark Uden
  • Publication number: 20130090259
    Abstract: The invention provides methods for the rapid identification and selection of cell lines suitable for biopharmaceuticals production, which do no utilize animal derived components.
    Type: Application
    Filed: June 29, 2011
    Publication date: April 11, 2013
    Inventors: Ekaterini Kotsopoulou, Richard C. Priest, Mark Uden
  • Publication number: 20110040074
    Abstract: The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities. Furthermore the methods of the invention also generate cell lines with lower concentrations of selection and amplification agent than previously achievable. Accordingly lower levels of selection and amplification marker in the final cells lines are observed.
    Type: Application
    Filed: August 19, 2008
    Publication date: February 17, 2011
    Inventors: Mark Uden, Ekaterini Kotsopoulou
  • Patent number: 7303910
    Abstract: A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (“NOI”); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (“NS”) capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: December 4, 2007
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Christopher Robert Bebbington, Susan Mary Kingsman, Mark Uden, Alan John Kingsman, Kyriacos Mitrophanos
  • Publication number: 20050009186
    Abstract: A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (“NOI”); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (“NS”) capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.
    Type: Application
    Filed: April 30, 2004
    Publication date: January 13, 2005
    Inventors: Christopher Bebbington, Susan Kingsman, Mark Uden, Alan Kingsman, Kyriacos Mitrophanos
  • Patent number: 6808922
    Abstract: A retroviral vector is described. The retroviral vector comprises a functional splice donor site and a functional splice acceptor site; wherein the functional splice donor site and the functional splice acceptor site flank a first nucleotide sequence of interest (“NOI”); wherein the functional splice donor site is upstream of the functional splice acceptor site; wherein the retroviral vector is derived from a retroviral pro-vector; wherein the retroviral pro-vector comprises a first nucleotide sequence (“NS”) capable of yielding the functional splice donor site and a second NS capable of yielding the functional splice acceptor site; wherein the first NS is downstream of the second NS; such that the retroviral vector is formed as a result of reverse transcription of the retroviral pro-vector.
    Type: Grant
    Filed: June 8, 2000
    Date of Patent: October 26, 2004
    Assignee: Oxford Biomedica Limited
    Inventors: Christopher Robert Bebbington, Susan Mary Kingsman, Mark Uden, Alan John Kingsman, Kyriacos Mitrophanos
  • Patent number: 6783981
    Abstract: A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles, (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product; wherein at least one of the gene products is an external guide sequence capable of binding to and effecting the cleavage by RNase P of the second nucleotide sequence.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: August 31, 2004
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Mark Uden, Kyriacos Mitrophanous
  • Publication number: 20020034393
    Abstract: A retroviral vector capable of delivering an NOI and comprising an exogenous second synthesis element.
    Type: Application
    Filed: May 18, 2001
    Publication date: March 21, 2002
    Inventors: Kyriacos A. Mitrophanous, Mark Uden, Jonathan Rohll, Susan Mary Kingsman, Alan John Kingsman